Inflexal V a trivalent virosome subunit influenza vaccine: production.
Inflexal V, a novel virosome-based trivalent influenza vaccine, has been shown to be highly immunogenic and well tolerated in children, young adults, and the elderly. Here we discuss the techniques for the manufacture of Inflexal V, highlighting the purity and consistency of the manufacturing process. Key factors to be taken into account in the construction of Inflexal V are the retention of the natural presentation of antigens, its biodegradability and the presentation of few adverse events. The constituents of the vaccine were also carefully considered based on suitability for human use, adjuvanticity and an innate lack of toxicity.
Mischler
Robert
R
Berna Biotech Ltd., Rehhagstr. 79, CH-3018 Berne, Switzerland. robert.mischler@bernabiotech.com
Metcalfe
Ian C
IC
D002626:Chemistry, Pharmaceutical; D004340:Drug Contamination; D004355:Drug Stability; D004356:Drug Storage; D006801:Humans; D007252:Influenza Vaccines / Q000138:chemical synthesis* / Q000276:immunology / Q000627:therapeutic use; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control; D013678:Technology, Pharmaceutical; D014611:Vaccination; D022721:Vaccines, Virosome / Q000138:chemical synthesis* / Q000276:immunology / Q000627:therapeutic use
C475022:Inflexal V; D007252:Influenza Vaccines; D022721:Vaccines, Virosome